pI: 7.7456 |
Length (AA): 906 |
MW (Da): 103033 |
Paralog Number:
0
Signal peptide: N | GPI Anchor: | Predicted trans-membrane segments: 1
Targets have been classified into druggability groups (DG) according to their druggability score in network driven prioritizations. DGs range from 1 to 5; the higher the group number, the higher the chance of the target to be druggable
Modbase 3D models:
There are 2 models calculated for this protein. More info on
these models, including the
models themselves is available at:
Modbase
Target Beg | Target End | Template | Template Beg | Template End | Identity | Evalue | Model Score | MPQS | zDope |
---|---|---|---|---|---|---|---|---|---|
111 | 897 | 1w6k (A) | 13 | 723 | 42.00 | 0 | 1 | 1.28565 | -0.56 |
218 | 892 | 2sqc (A) | 10 | 626 | 23.00 | 0 | 1 | 0.966033 | -0.41 |
Help me make sense of these data.
A more detailed description of these scores is available at the Modbase Model Evaluation Help Pages, and in the papers referenced therein.
PDB Structures:
Upregulation Percent | Ranking | Stage | Dataset |
---|---|---|---|
Upper 80-100% percentile | Procyclic. | Siegel TN |
Upregulation Percent | Ranking | Stage | Dataset |
---|---|---|---|
Upper 60-80% percentile | Bloodstream Form. | Siegel TN |
Siegel TN | Genome-wide analysis of mRNA abundance in two life-cycle stages of Trypanosoma brucei and identification of splicing and polyadenylation sites. |
Ortholog group members (OG5_127966)
Species | Accession | Gene Product |
---|---|---|
Arabidopsis thaliana | AT4G15340 | pentacyclic triterpene synthase 1 |
Arabidopsis thaliana | AT1G78970 | lupeol synthase 1 |
Arabidopsis thaliana | AT5G36150 | tirucalladienol synthase |
Arabidopsis thaliana | AT3G45130 | lanosterol synthase 1 |
Arabidopsis thaliana | AT5G42600 | marneral synthase |
Arabidopsis thaliana | AT5G48010 | thalianol synthase 1 |
Arabidopsis thaliana | AT1G78950 | beta-amyrin synthase |
Arabidopsis thaliana | AT1G78960 | lupeol synthase 2 |
Arabidopsis thaliana | AT1G78955 | camelliol C synthase 1 |
Arabidopsis thaliana | AT1G66960 | Terpenoid cyclases family protein |
Arabidopsis thaliana | AT2G07050 | cycloartenol synthase |
Arabidopsis thaliana | AT3G29255 | putative pentacyclic triterpene synthase 7 |
Arabidopsis thaliana | AT4G15370 | baruol synthase 1 |
Arabidopsis thaliana | AT1G78500 | pentacyclic triterpene synthase 6 |
Candida albicans | CaO19.9143 | 2,3-oxidosqualene-lanosterol cyclase |
Candida albicans | CaO19.1570 | 2,3-oxidosqualene-lanosterol cyclase |
Dictyostelium discoideum | DDB_G0269226 | cycloartenol synthase |
Homo sapiens | ENSG00000160285 | lanosterol synthase (2,3-oxidosqualene-lanosterol cyclase) |
Leishmania braziliensis | LbrM.06.0650 | lanosterol synthase, putative |
Leishmania donovani | LdBPK_060670.1 | lanosterol synthase, putative |
Leishmania infantum | LinJ.06.0670 | lanosterol synthase, putative |
Leishmania major | LmjF.06.0650 | lanosterol synthase, putative |
Leishmania mexicana | LmxM.06.0650 | lanosterol synthase, putative |
Mus musculus | 16987 | lanosterol synthase |
Oryza sativa | 4328259 | Os02g0140200 |
Oryza sativa | 4350295 | Os11g0286800 |
Oryza sativa | 9268610 | Os11g0189600 |
Oryza sativa | 4328261 | Os02g0140400 |
Oryza sativa | 4328256 | Os02g0139700 |
Oryza sativa | 4328254 | Os02g0139500 |
Oryza sativa | 4344966 | Os08g0223900 |
Oryza sativa | 4350288 | Os11g0285000 |
Oryza sativa | 4350734 | Os11g0562100 |
Saccharomyces cerevisiae | YHR072W | lanosterol synthase ERG7 |
Trypanosoma brucei gambiense | Tbg972.7.6010 | lanosterol synthase |
Trypanosoma brucei | Tb927.7.5230 | lanosterol synthase |
Trypanosoma congolense | TcIL3000_0_16660 | lanosterol synthase |
Trypanosoma cruzi | TcCLB.506825.170 | lanosterol synthase, putative |
Trypanosoma cruzi | TcCLB.508175.70 | lanosterol synthase, putative |
Gene/Ortholog | Organism | Phenotype | Source Study |
---|---|---|---|
Tb927.7.5230 this record | Trypanosoma brucei | no significant loss or gain of fitness in bloodstream forms (3 days) | alsford |
Tb927.7.5230 this record | Trypanosoma brucei | no significant loss or gain of fitness in bloodstream forms (6 days) | alsford |
Tb927.7.5230 this record | Trypanosoma brucei | no significant loss or gain of fitness in procyclic forms | alsford |
Tb927.7.5230 this record | Trypanosoma brucei | no significant loss or gain of fitness in differentiation of procyclic to bloodstream forms | alsford |
YHR072W | Saccharomyces cerevisiae | inviable | yeastgenome |
gerdes | Experimental determination and system-level analysis of essential genes in E. coli MG1655 | Gerdes et al., J Bacteriol. 2003 185:5673-84 |
keio | Systematic single-gene knock-out mutants of E. coli K12 | The Keio Collection |
alsford | High-throughput phenotyping using parallel sequencing of RNA interference targets in the African trypanosome | Genome Res 2011, 21:915-924 |
neb | C. elegans RNAi phenotypes | Data obtained from Wormbase WS150, curated by K. Chaudary and T. Carlow, New England Biolabs |
wormbase | C. elegans RNAi experiments | WormBase web site, http://www.wormbase.org, release WS170 |
blattner | Systematic mutagenesis of the E. coli (MG1655) genome | J Bacteriol 2004, 186:4921-4930 |
yeastgenome | Systematic deletion of yeast genes | Saccharomyces Genome Database |
nmpdr | Genome-scale essentiality datasets from published studies (M. tuberculosis) | National Microbial Pathogen Data Resource |
shigen | Profiling of E. coli Chromosome (PEC) | National Institute of Genetics, Japan |
Affected Entity | Phenotypic quality | Occurs in | Occurs at | Evidence | Observed in | Drugs/Inhibitors |
---|---|---|---|---|---|---|
cell proliferation (GO:0008283) | normal (PATO:0000461) | bloodstream stage trypomastigotes (PLO:0027) | inferred from RNAi experiment (ECO:0000019) | No drug identifiers listed for this gene. | ||
Annotator: | fernan@iib.unsam.edu.ar. | Comment: | normal cell proliferation (no significant loss or gain of fitness) in bloodstream forms (stage 6 days). | References: | 21363968 | |
cell proliferation (GO:0008283) | normal (PATO:0000461) | procyclic (PLO:0034) | inferred from RNAi experiment (ECO:0000019) | No drug identifiers listed for this gene. | ||
Annotator: | fernan@iib.unsam.edu.ar. | Comment: | normal cell proliferation (no significant loss or gain of fitness) in differentiation of procyclic to bloodstream forms . | References: | 21363968 |
In TDR Targets, information about phenotypes that are caused by drugs, or by genetic manipulation of cells (e.g. gene knockouts or knockdowns) is manually curated from the literature. These descriptions help to describe the potential of the target for drug development. If no information is available for this gene or if the information is incomplete, this may mean that i) the papers containing this information either appeared after the curation effort for this organism was carried out or they were inadvertently missed by curators; or that ii) the curation effort for this organism has not yet started.
In any case, if you have information about papers containing relevant validation data for this target, please contact us.
Druggability index (range: 0 to 1): 0.6
Species | Known druggable target | Linked compounds | Reference |
---|---|---|---|
Homo sapiens | lanosterol synthase (2,3-oxidosqualene-lanosterol cyclase) | Compounds | References |
Pneumocystis carinii | Lanosterol synthase | Compounds | References |
Arabidopsis thaliana | cycloartenol synthase | Compounds | References |
Trypanosoma cruzi | lanosterol synthase, putative | Compounds | References |
Candida albicans | 2,3-oxidosqualene-lanosterol cyclase | Compounds | References |
Saccharomyces cerevisiae | lanosterol synthase ERG7 | Compounds | References |
Rattus norvegicus | Lanosterol synthase | Compounds | References |
Alicyclobacillus acidocaldarius subsp. acidocaldarius (strain ATCC27009 / DSM 446 / 104-1A) (Bacillu | Squalene-hopene cyclase | Compounds | References |
Trypanosoma cruzi | lanosterol synthase, putative | Compounds | References |
1 literature reference was collected for this gene.